Although not yet used in human IBD, the TLR3 agonist rintatolimod has benefits in chronic fatigue syndrome/myalgic encephalomyelitis (215, 216), a disease of uncertain etiology but with evidence of viral triggers to the disease and impaired natural killer cell function (217). Here, TLR3 is linked to inflammatory bowel disease.